Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Roche_Pharma
|
| gptkbp:class |
gptkb:monoclonal_antibody
|
| gptkbp:clinical_trial |
gptkb:unknown
NC T04327388 NC T04356937 NC T04372186 NC T04409262 |
| gptkbp:contraindication |
active infections
severe liver impairment history of gastrointestinal perforation hypersensitivity to tocilizumab |
| gptkbp:dosage_form |
solution for infusion
solution for injection |
| gptkbp:effective_date |
2010-01-08
|
| gptkbp:excretion |
biliary
|
| gptkbp:formulation |
lyophilized powder
auto-injector pre-filled syringe |
| https://www.w3.org/2000/01/rdf-schema#label |
Actemra
|
| gptkbp:indication |
gptkb:systemic_juvenile_idiopathic_arthritis
moderate to severe rheumatoid arthritis severe COVID-19 pneumonia severe cytokine release syndrome |
| gptkbp:ingredients |
gptkb:tocilizumab
C_20 H_21 N_3 O_6 S |
| gptkbp:invention |
2026-03-01
|
| gptkbp:is_atype_of |
L04 A C07
|
| gptkbp:is_used_for |
gptkb:giant_cell_arteritis
gptkb:healthcare_organization gptkb:COVID-19 gptkb:rheumatoid_arthritis |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
approximately 13 days
|
| gptkbp:manager |
intravenous
subcutaneous |
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
hepatic
|
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:safety_features |
blood tests for liver function
complete blood count monitoring lipid levels monitoring monitoring for infections |
| gptkbp:side_effect |
fatigue
headache nausea allergic reactions rash increased risk of infections injection site reactions gastrointestinal perforations elevated liver enzymes |
| gptkbp:targets |
gptkb:IL-6_receptor
|